Therefore, it is important to develop novel and effective alternative treatments for ALK+ DLBCL, including front-line intensification with or without autologous stem-cell transplantation, and the application of new biological agents such as anti-CD138 monoclonal antibodies and ALK inhibitors (14,15). The gene discussed is SDC1; the disease is diffuse large B-cell lymphoma.